MSON - Bioventus provides Q2 prelim net sales updates FY guidance; acquires Misonix for $518M

Bioventus (NASDAQ:BVS) expects Q2 prelim net sales to be in the range of $108 to $110M represents 86.2% to 89.7% Y/Y. Analysts consensus estimates for Q2 net sales stands at $97.64M. The sales comprises of net sales from legacy Bioventus of $96.5 to $98M (+66.4% to 69% Y/Y) and net sales from the acquisition of Bioness of $11.5 to $12M. The company also updated FY21 net sales guidance with net sales of $405 to $415M (+26% to 29% Y/Y) which includes net sales from legacy Bioventus representing organic revenue growth in the range of ~16% to 18% Y/Y. Q2 results are scheduled for Aug.10 release. Separately, Bioventus announced that it will acquire Misonix (NASDAQ:MSON) in a cash and stock transaction wherein Misonix stockholders will receive total consideration that values Misonix at ~$518M on a fully-diluted basis. In the transaction, Misonix stockholders may elect to receive either 1.6839 shares of Bioventus class

For further details see:

Bioventus provides Q2 prelim net sales, updates FY guidance; acquires Misonix for $518M